Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility
| Autor: | Ricardo Valjalo, Eduardo Lorca, Fernando E Figueroa, Juan Carreno, Jorge Bartolucci, Andrés Tapia, Maroun Khoury, Sandra Villanueva, Rocío Strodthoff, Francisca Fajre, Manuel Lecanda, César Vergara, Valentina G López, Fernando González |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adipose tissue-derived mesenchymal stromal cells
medicine.medical_specialty lcsh:Internal medicine lcsh:Specialties of internal medicine Mesenchymal stromal cell transplantation 030232 urology & nephrology Urology Adipose tissue Renal function Stem cells 030204 cardiovascular system & hematology Excretion 03 medical and health sciences 0302 clinical medicine lcsh:RC581-951 Chronic kidney disease Medicine Adverse effect lcsh:RC31-1245 Proteinuria business.industry Mesenchymal stem cell General Medicine medicine.disease Original Article Stem cell medicine.symptom business Kidney disease |
| Zdroj: | Kidney Research and Clinical Practice, Vol 38, Iss 2, Pp 176-185 (2019) Kidney Research and Clinical Practice |
| ISSN: | 2211-9132 |
| Popis: | Background : Chronic kidney disease (CKD) is a growing public health concern, and available treatments are insufficient in limiting disease progression. New strategies, including regenerative cell-based therapies, have emerged as therapeutic alternatives. Results : from several groups, including our own, have reported evidence of a supportive role for mesenchymal stromal cells (MSCs) in functional recovery and prevention of tissue damage in murine models of CKD. Prompted by these data, an open pilot study was conducted to assess the safety and efficacy of a single injection of autologous adipose tissue-derived MSCs (AT-MSCs) for treatment of CKD. Methods : AT-MSCs were infused intravenously into six CKD patients at a dose of 1 million cells/kg. Patients were stabilized and followed for one year prior to MSC infusion and one year following infusion. Results : No patients presented with adverse effects. Statistically significant improvement in urinary protein excretion was observed in AT-MSCs transplanted patients, from a median of 0.75 g/day (range, 0.15-9.57) at baseline to 0.54 g/day (range, 0.01v2.66) at month 12 (P = 0.046). The glomerular filtration rate was not significantly decreased post-infusion of AT-MSCs. Conclusion : Findings from this pilot study demonstrate that intravenous infusion of autologous expanded AT-MSCs into CKD patients was not associated with adverse effects and could benefit patients already undergoing standard medical treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|